Reversal of residue-specific ADP-ribosylations by ADP-ribosyl-acceptor hydrolases
ADP-核糖基受体水解酶逆转残基特异性 ADP-核糖基化
基本信息
- 批准号:10183062
- 负责人:
- 金额:$ 33.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:ADP ribosylationArginineBacterial ToxinsBiological AssayBiological ProcessCatalysisCell DeathCellsCholera ToxinCleaved cellComplexDNA DamageDataDiphtheria ToxinDiseaseEngineeringEnzymesFamilyFluorescenceFluorescence Resonance Energy TransferGene ExpressionGenomic InstabilityHomeostasisHydrolaseHydrolysisIn VitroInjuryKineticsLifeLigand BindingLinkMalignant NeoplasmsMeasurementMeasuresMetal Binding SiteMetalsMethodsModificationMolecular ConformationMonitorNatural ImmunityNatureNerve DegenerationNormal RangePathologicPeptidesPhysiologyPlayPoly Adenosine Diphosphate RibosePost-Translational Protein ProcessingProcessProteinsRadioactiveRegulationRoleSeriesSerineSignal TransductionSiteSpecificityStructureSurgical incisionsTestingTimeTransferasebasecytotoxicitygenome integritygenotoxicitymetalloenzymemutantnovelresponsetool
项目摘要
Abstract
Residue-specific, reversible protein ADP-ribosylations regulate a broad range of biological processes, including
DNA damage responses, gene expression, and cell death. Therefore, homeostasis of cellular ADP-
ribosylations is essential for maintaining genomic integrity. ADP-ribosyl-acceptor hydrolases (ARHs) are a
family of metalloenzymes that regulate site-specific ADP-ribosylations. ARH3 specifically reverses poly(ADP-
ribose) and mono-ADP-ribosylation at serine, a major site for modification following DNA damage, whereas
ARH1 cleaves mono-ADP-ribosylation at arginine. However, there is a fundamental gap in understanding of
substrate selectivity, catalysis, and function of specific activities of ARHs, which is largely due to the lack of
quantitative and convenient tools and insufficient structural information on substrate-bound active forms. The
objective of this application is to develop novel quantitative assays that selectively measure the reversal of
residue-specific ADP-ribosylations and to elucidate the mechanism of substrate selectivity and the role of each
enzymatic activity of ARH3. In support of this objective, we have developed a highly sensitive, quantitative, and
convenient fluorescence-based assays that specifically monitor the reversal of poly(ADP-ribose) or serine
mono-ADP-ribosylation by ARH3. We have also determined initial structures of ARH3 bound to intact
substrates. Guided by these strong preliminary data, we will pursue three specific aims to test our hypothesis
that the metal-coordination states and unique structural plasticity of ARHs are linked to substrate selectivity
and efficient catalysis. In Aim 1, we will fully develop quantitative fluorescence-based assays that selectively
monitor the reversal of residue-specific mono-ADP-ribosylations. In Aim 2, we will determine the structural
bases for the specific substrate recognition and cleavage by ARHs. In Aim 3, we will identify ARH3 separation-
of-function mutants to define the role of each enzymatic activity of ARH3. Our studies will provide new
quantitative tools to study diverse ADP-ribosylation-metabolizing enzymes in nature and advance our
understanding of the mechanisms and functions of ARHs as essential processes for maintaining life.
摘要
残基特异性可逆的蛋白质ADP-核糖基化调节广泛的生物过程,包括
DNA损伤反应、基因表达和细胞死亡。因此,细胞内ADP-
核糖基化是维持基因组完整性所必需的。ADP-核糖基受体水解酶(ARH)是一种
调节位点特异性ADP核糖基化的金属酶家族。ARH 3特异性逆转poly(ADP-
核糖)和丝氨酸处的单ADP核糖基化,丝氨酸是DNA损伤后修饰的主要位点,而
ARH 1在精氨酸处切割单ADP核糖基化。然而,在理解上存在着根本性的差距,
底物的选择性,催化作用,和功能的比活性的ARHs,这在很大程度上是由于缺乏
定量和方便的工具以及关于底物结合的活性形式的结构信息不足。的
本申请的目的是开发新的定量分析,其选择性地测量逆转的
残基特异性ADP-核糖基化,并阐明底物选择性的机制和各自的作用
ARH 3的酶活性。为了支持这一目标,我们制定了一个高度敏感的,定量的,
方便的基于荧光的测定,其特异性地监测聚(ADP-核糖)或丝氨酸
通过ARH 3的单ADP核糖基化。我们还确定了ARH 3的初始结构,
印刷受体.在这些强有力的初步数据的指导下,我们将追求三个具体目标来检验我们的假设
ARHs的金属配位状态和独特的结构可塑性与底物选择性有关
和高效催化。在目标1中,我们将全面开发基于荧光的定量分析,
监测残基特异性单ADP核糖基化的逆转。在目标2中,我们将确定结构
用于特定底物识别和ARH切割的碱基。在目标3中,我们将确定ARH 3分离-
功能突变体,以确定ARH 3的每种酶活性的作用。我们的研究将提供新的
研究自然界中各种ADP核糖基化代谢酶的定量工具,
了解ARH的机制和功能是维持生命的基本过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
In-Kwon Kim其他文献
In-Kwon Kim的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('In-Kwon Kim', 18)}}的其他基金
Reversal of residue-specific ADP-ribosylations by ADP-ribosyl-acceptor hydrolases
ADP-核糖基受体水解酶逆转残基特异性 ADP-核糖基化
- 批准号:
10794697 - 财政年份:2021
- 资助金额:
$ 33.49万 - 项目类别:
Reversal of residue-specific ADP-ribosylations by ADP-ribosyl-acceptor hydrolases
ADP-核糖基受体水解酶逆转残基特异性 ADP-核糖基化
- 批准号:
10392422 - 财政年份:2021
- 资助金额:
$ 33.49万 - 项目类别:
Reversal of residue-specific ADP-ribosylations by ADP-ribosyl-acceptor hydrolases
ADP-核糖基受体水解酶逆转残基特异性 ADP-核糖基化
- 批准号:
10574486 - 财政年份:2021
- 资助金额:
$ 33.49万 - 项目类别:
相似国自然基金
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment
9p21.3 缺失肿瘤微环境中的靶向蛋白精氨酸甲基化
- 批准号:
489995 - 财政年份:2023
- 资助金额:
$ 33.49万 - 项目类别:
Operating Grants
The role of protein arginine methyl transferase PRMT1 on myelin development
蛋白精氨酸甲基转移酶PRMT1对髓磷脂发育的作用
- 批准号:
23K14287 - 财政年份:2023
- 资助金额:
$ 33.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Normalizing arginine metabolism with sepiaptein for immunostimulatory-shift ofHER2+ breast cancer
使用 Sepiaptein 使精氨酸代谢正常化以实现 HER2 乳腺癌的免疫刺激转变
- 批准号:
10776256 - 财政年份:2023
- 资助金额:
$ 33.49万 - 项目类别:
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
精氨酸消耗联合铂类紫杉烷化疗对侵袭性变异前列腺癌 (AVPC) 的影响
- 批准号:
10715329 - 财政年份:2023
- 资助金额:
$ 33.49万 - 项目类别:
Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma
了解淋巴瘤对蛋白精氨酸甲基转移酶抑制剂的耐药机制
- 批准号:
10668754 - 财政年份:2023
- 资助金额:
$ 33.49万 - 项目类别:
Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment
9p21.3 缺失肿瘤微环境中的靶向蛋白精氨酸甲基化
- 批准号:
498862 - 财政年份:2023
- 资助金额:
$ 33.49万 - 项目类别:
Operating Grants
Physiological function of arginine signaling:macropinocytosisand tumor immune evasion
精氨酸信号的生理功能:巨胞饮作用与肿瘤免疫逃避
- 批准号:
23H03317 - 财政年份:2023
- 资助金额:
$ 33.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 33.49万 - 项目类别:
Arginine methylation of the RNA helicase DDX5 in the regulation of RNA/DNA hybrids during the DNA damage response.
RNA 解旋酶 DDX5 的精氨酸甲基化在 DNA 损伤反应期间调节 RNA/DNA 杂交体中的作用。
- 批准号:
487619 - 财政年份:2023
- 资助金额:
$ 33.49万 - 项目类别:
Operating Grants
Regulation of and Target Recognition by Protein Arginine Methyltransferase 1 (PRMT1)
蛋白质精氨酸甲基转移酶 1 (PRMT1) 的调节和目标识别
- 批准号:
10653465 - 财政年份:2023
- 资助金额:
$ 33.49万 - 项目类别: